HER2 Support Group Forums - View Single Post - Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation

News · 01-16-2013, 11:21 PM

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

More...

01-16-2013, 11:21 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,966	Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). More...